Advertisement

Screening for Diabetic Retinopathy

  • Ruth Davies
  • Sally C. Brailsford
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 70)

Summary

A discrete event simulation describes the screening and natural history of eye disease in patients with diabetes, using the POST simulation software. Discrete event simulation, unlike other modeling techniques, can show the interaction between screening and the two main diabetic eye disease processes. Results show that there is a tradeoff between screening frequency, screening sensitivity and patient compliance. The extent to which screening is cost effective is not clear cut. We have little data on the cost of blindness and different views on the appropriate quality-of-life values to assume. The model can be extended to evaluate prevention and treatment for all the complications of diabetes.

Key words

Diabetes Simulation Blindness Cost-effectiveness 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Gatling, W., S. Budd, D. Walters, M.A. Mullee, J.R. Goddard, and R.D. Hill (1998). Evidence of an increasing prevalence of diagnosed diabetes mellitus in the Poole area from 1983 to 1996. Diabetic Medicine, 15, 1015–1021.CrossRefPubMedGoogle Scholar
  2. [2]
    Early Treatment Diabetic Retinopathy Study Research Group (1991). Early photocoagulation for diabetic retinopathy: ETDRS report No 92. Ophthalmology, 98, 766–785.Google Scholar
  3. [3]
    Klein, R., B.E.K. Klein, S.E. Moss SE, and K.J. Cruikshanks (1994). The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Archives of Ophthalmology, 112, 1217–28.PubMedGoogle Scholar
  4. [4]
    Klein, R., B.E.K. Klein, and S.E. Moss (1984). Visual impairment in diabetes. Ophthalmology, 91, 1–9.PubMedGoogle Scholar
  5. [5]
    Wilson, J.M.G. and O. Junner (1968). The principles and practice of screening for disease. Public Health Papers, 34, Geneva: WEW.Google Scholar
  6. [6]
    Bagga, P., D. Verma, C. Walton, et al. (1998). Survey of diabetic retinopathy screening services in England and Wales. Diabetic Medicine, 15, 780–782.CrossRefPubMedGoogle Scholar
  7. [7]
    NHS Centre for Reviews and Dissemination (1999). Complications of diabetes: screening for retinopathy, management of foot ulcers. Effective Health Care, 5.Google Scholar
  8. [8]
    Klein, R., S.E. Moss, B.E.K. Klein, M.D. Davies, and D.L. De Mets (1989). The Wisconsin Epidemiologic Study of Diabetic Retinopathy XI. The incidence of macular edema. Ophthalmology, 96, 1501–1510.PubMedGoogle Scholar
  9. [9]
    Klein, R., B.E.K. Klein, S.E. Moss, M.D. Davis, and D.L. De Mets (1989). The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology, 107, 237–243.PubMedGoogle Scholar
  10. [10]
    Diabetic Retinopathy Study Research Group (1981). Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings. DRS Report No. 8. Ophthalmology, 88, 583–600.Google Scholar
  11. [11]
    UK Prospective Diabetes Study (UKPDS) Group (1991). UK Prospective Diabetes Study. VII. Study design, progress and performance. Diabetologia, 34, 877–890.Google Scholar
  12. [12]
    Dasbach, E.J., D.G. Fryback, P.A. Newcomb, R. Klein and B.E.K. Klein (1991). Cost-effectiveness of strategies for detecting diabetic retinopathy. Medical Care, 29, 20–39.PubMedGoogle Scholar
  13. [13]
    Bachmann, M. and S. Nelson (1998). Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. Journal of Epidemiology and Community Health, 52, 45–52.PubMedGoogle Scholar
  14. [14]
    Tomar, R.H., S. Lee, S.-Y. Wu, R. Klein, B.E.K. Klein, S.E. Moss, D.G. Flyback, J.L. Tollios and F. Sainfort (1998). Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model. Journal of the Society for Health Systems, 5, 24–37.PubMedGoogle Scholar
  15. [15]
    Vijan, S., T.P. Hofer, and R.A. Hayward (2000). Cost utility of screening intervals for diabetic retinopathy in patients with Type 2 Diabetes Mellitus. Journal of the American Medical Association, 283, 889–896.CrossRefPubMedGoogle Scholar
  16. [16]
    James, M., D.A. Turner, D.M. Broadbent, J. Vora, and S.P. Harding (2000). Cost effectiveness of screening for sight threatening diabetic eye disease. British Medical Journal, 320, 1627–1631.PubMedGoogle Scholar
  17. [17]
    Javitt, J.C., J.K. Canner, and A. Sommer (1989). Cost effectiveness of current approaches to the control of retinopathy in Type 1 diabetics. Ophthalmology, 96, 255–264.PubMedGoogle Scholar
  18. [18]
    Javitt, J.C., L.P. Aiello, L.J. Bassi, Y.P. Chiang and J.K. Canner (1991). Detecting and treating retinopathy in patients with Type 1 diabetes mellitus. Ophthalmology, 98, 1561–1573.Google Scholar
  19. [19]
    Javitt, J.C., L.P. Aiello, Y.P. Chiang, F.L. Ferris, J.K. Canner, and S. Greenfield (1994). Preventive eye care in people with diabetes is cost-saving to the federal government. Diabetes Care, 17, 909–917.PubMedGoogle Scholar
  20. [20]
    Javitt, J.C. and L. Aiello (1996). Cost-effectiveness and detecting and treating diabetes. Annals of Internal Medicine, 124, 164–169.PubMedGoogle Scholar
  21. [21]
    Dyck, P.J., K.M. Kratz, J.L. Kames, W.J. Litchy, R. Klein, J.M. Pach, D.M. Wilson, P.C. O’Brien, and L.J. Melton. III (1993). The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology, 43, 817–824.PubMedGoogle Scholar
  22. [22]
    Eastman, R.C., J.C. Javitt, W.H. Herman, E.J. Dasbach, A.S. Zbrozeh, F. Dong, et al. (1997). Model of complications of NIDDM. Model construction and assumptions. Diabetes Care, 20, 725–24.PubMedGoogle Scholar
  23. [23]
    Javitt, J.C. (2000). How often should patients with diabetes be screened for retinopathy? (letter). Journal of the American Medical Association, 284, 437.CrossRefPubMedGoogle Scholar
  24. [24]
    Davies, H.T.O. and R. Davies (1995). Simulating health systems: modelling problems and software solutions. European Journal of Operational Research, 87, 35–44.CrossRefGoogle Scholar
  25. [25]
    Davies, R. and H.T.O. Davies (1994). Modelling patient flows and resource provision in health systems. Omega International Journal of Management Science, 22, 123–131.Google Scholar
  26. [26]
    Davies, R., P. Sullivan, and C. Canning (1996). Simulation of diabetic eye disease to compare screening policies. British Journal of Ophthalmology, 80, 945–950.PubMedGoogle Scholar
  27. [27]
    Brailsford, S.C., R. Davies, C. Canning, and P. Roderick (1998). Evaluating screening policies for the early detection of retinopathy in patients with non-insulin-dependent diabetes. Health Care Management Science, 1, 115–124.CrossRefPubMedGoogle Scholar
  28. [28]
    Davies, R., S.C. Brailsford, P. Roderick, C. Canning, and D. Crabbe (2000). Using simulation modeling for evaluating screening services for diabetic retinopathy. Journal of the Operational Research Society, 51, 476–484.CrossRefGoogle Scholar
  29. [29]
    Davies, R., P. Roderick, C. Canning, and S.C. Brailsford (2002). The evaluation of screening policies for diabetic retinopathy using simulation. Diabetic Medicine, 19(9), 763–771.CrossRefGoogle Scholar
  30. [30]
    Brailsford, S.C. and R. Davies (2001). Screening for Diabetic Retinopathy. www.management.soton.ac.uk/retinopathy/Google Scholar
  31. [31]
    Reenders, K., E. de Noble, H. van den Hoogen, and C. van Weel (1992). Screening for diabetic retinopathy by general practitioners. Scandinavian Primary Health Care, 10, 306–309.Google Scholar
  32. [32]
    Pugh, J.A., J.M. Jacobson, W.A. Van Heuven, et al. (1993). Screening for diabetic retinopathy. The wide angle retinal camera. Diabetes Care, 16, 889–895.PubMedGoogle Scholar
  33. [33]
    NHS NSC Diabetic Retinopathy Screening (2001). Resources for a National Diabetic Risk-reduction Programme, www.diabetic-retinopathy.screening.nhs.uk/costings.html.Google Scholar
  34. [34]
    Netten, A. and J. Dennett (1996). Unit Costs of Community Care. Personal Social Services Research Unit, University of Kent.Google Scholar
  35. [35]
    Bailey, C.C., J.M. Sparrow, R.H. Grey, and H. Cheng (1999). The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes. Eye, 13, 151–159.PubMedGoogle Scholar
  36. [36]
    Raftery, J. (2000). Methodological limitations of cost effectiveness analysis on health care: implications for decision making and service provision. Journal of Evaluation in Clinical Practice, 5, 361–365.Google Scholar
  37. [37]
    Eastman, R.C., J.C. Javitt, W.H. Herman, et al. (1997). Model of complications of NIDDM II, analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care, 20, 735–744.PubMedGoogle Scholar
  38. [38]
    Dummond, M. (1987). Consultant Report to the National Eye Institute. National Eye Institute, Bethesda, MD.Google Scholar
  39. [39]
    Torrance, G.W. and D. Feeny (1989). Utilities and quality adjusted life years. International Journal of Technology Assessment in Health Care, 2, 559–575.Google Scholar
  40. [40]
    Brown, M.B., G.C. Brown, S. Sharma, and G. Shah (1999). Utility values and diabetic retinopathy. American Journal of Ophthalmology, 128, 324–330.PubMedGoogle Scholar
  41. [41]
    Brown, G.C. (1999). Vision and quality of life. Transactions of the American Ophthalmology Society, 92, 474–511.Google Scholar
  42. [42]
    Gold, M.R., J.E. Siegel, L.B. Russell, and M. Weinstein, Eds. (1996). Cost Effectiveness in Health and Medicine. Oxford University Press, New YorkGoogle Scholar
  43. [43]
    National Institute for Clinical Excellence (2001), Guidance for Manufacturers and sponsors. www.nice.org.uk/Docref.asp?d=16183.Google Scholar
  44. [44]
    Wright, S.E., J.E. Keeffe, and L.S. Thies (2000). Direct costs of blindness in Australia. Clinical and Experimental Ophthalmology, 28, 140–142.CrossRefPubMedGoogle Scholar
  45. [45]
    Davies, R., P. Roderick, and J. Raftery (2003). The evaluation of disease prevention and treatment using simulation models. European Journal of Operational Research, 150, 53–66.CrossRefGoogle Scholar
  46. [46]
    Davies, R. and P. Roderick (1998). Planning resources for renal services throughout England using simulation. European Journal of Operational Research, 105, 285–295.CrossRefGoogle Scholar
  47. [47]
    Brailsford, S.C., A.K. Shahani, R. Basu Roy, and S. Sivapalan (1996). Practical models for the care of HIV and AIDS patients. International Journal of STD and AIDS, 7, 91–97.PubMedGoogle Scholar
  48. [48]
    Davies, R., R. Roderick, D. Crabbe, J. Raftery, P. Patel, and J.R. Goddard (2002). A simulation to evaluate screening for helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Management Science, 5, 249–258.CrossRefPubMedGoogle Scholar
  49. [49]
    Babad, H., C. Sanderson, B. Naidoo, I. White, and D. Wang (2002). The development of a model for the prevention of coronary heart disease. Health Care Management Science, 5, 269–274.CrossRefPubMedGoogle Scholar
  50. [50]
    Cooper, K., R. Davies, P. Roderick, D. Chase, and J. Raftery (2002). The development of a simulation model for the treatment of coronary artery disease. Health Care Management Science, 5, 259–267.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Ruth Davies
    • 1
  • Sally C. Brailsford
    • 2
  1. 1.Warwick Business SchoolUniversity of WarwickCoventryUK
  2. 2.School of ManagementUniversity of SouthamptonSouthamptonUK

Personalised recommendations